Form 4: Heron Therapeutics Director Adam Morgan Reports Stock and Option Transactions

Director Adam Morgan of Heron Therapeutics reported the acquisition of restricted stock units and stock options, along with indirect ownership of a large block of common stock through Velan Capital Master Fund LP.

Summary

• Adam Morgan, a director at Heron Therapeutics, filed a Form 4 detailing recent transactions.
• On January 30, 2025, Mr. Morgan acquired 17,950 restricted stock units, which will vest on January 30, 2026.
• He also acquired 35,900 stock options with an exercise price of $1.73, vesting monthly over 12 months starting one month after the grant date, and expiring on January 30, 2035.
• Mr. Morgan indirectly owns 6,986,744 shares of common stock through Velan Capital Master Fund LP.
• Mr. Morgan disclaims beneficial ownership of the shares held by Velan Capital Master Fund LP except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of insider transactions, which is neither particularly positive nor negative. The transactions are standard practice and do not indicate any significant change in the company's outlook.

Positives

• The acquisition of restricted stock units and stock options by a director could be seen as a positive sign of confidence in the company's future performance.
• The vesting schedule of the stock options provides a long-term incentive for the director.

Risks

• The large indirect holding of shares through Velan Capital Master Fund LP could potentially lead to significant market movements if those shares were to be sold.
• The vesting of the restricted stock units and stock options could create future dilution if exercised.

Management Comments

• Mr. Morgan disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

Industry Context

This filing is a routine disclosure of insider transactions, which is common in the pharmaceutical industry where stock-based compensation is frequently used.

Comparison to Industry Standards

• Stock option grants and restricted stock units are common forms of compensation for directors and executives in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• The vesting schedules and exercise prices are typical for such grants, aligning with industry norms for incentivizing long-term performance.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment due to the director's increased stake in the company.
• The vesting of stock options and restricted stock units could lead to future dilution, which may have a minor negative impact on existing shareholders.

Key Dates

Keywords

Form 4, Heron Therapeutics, Adam Morgan, stock options, restricted stock units, insider trading, Velan Capital Master Fund LP, beneficial ownership